Certara Investor Day Presentation Deck slide image

Certara Investor Day Presentation Deck

Insights from the COVID-19 CODEX database Funded by the Bill and Melinda Gates Foundation, now includes 482 COVID-19 trials and real-world studies Comparison of RCTs and RWSS by COVID Treatment Overall Not randomized (n=112) Randomized (n=77) Anti-IL-6 Not randomized (n=38) Randomized (n=14) Antimalarial Not randomized (n=26) Randomized (n=24) Antiviral Not randomized (n=12) Randomized (n=19) Glucocorticoid Not randomized (n=28) Randomized (n=9) Plasma therapy Not randomized (n=13) Randomized (n=14) 0.250 0.500 Odds Ratio of Death 1.000 Real world studies (RWS) Randomized controlled trials (RCT) 2.000 ● ● ● ● ● Real world studies overestimated COVID treatment effects compared to randomized controlled trials Sheds important insights on how to bridge between real world studies and RCTs Valuable across all areas from rare diseases to viral pandemics CODEX can be used to create synthetic control arms Growing regulatory support for real-world evidence FDA U.S. FOOD & DRUG ADMINISTRATION FRAMEWORK FOR FDA'S REAL-WORLD EVIDENCE PROGRAM Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry 67 CERTARA
View entire presentation